Cover Feature: Advances in Diclofenac Derivatives: Exploring Carborane-Substituted N-Methyl and Nitrile Analogs for Anticancer Therapy (ChemMedChem 11/2025)

IF 3.6 4区医学 Q2 CHEMISTRY, MEDICINAL

ChemMedChem Pub Date : 2025-06-03 DOI:10.1002/cmdc.202581102

Christoph Selg, Robert Schuster, Aleksandr Kazimir, Peter Lönnecke, Mara Wolniewicz, Jonas Schädlich, Markus Laube, Jens Pietzsch, Vuk Gordić, Tamara Krajnović, Sanja Mijatović, Danijela Maksimović-Ivanić, Evamarie Hey-Hawkins

引用次数: 0

Abstract

Just as spikes help to deter birds from landing on building facades, strategic N-methylation in carborane-substituted diclofenac prevents the carboxylic acid from unwanted lactam formation, thus maintaining the open-chain structure for exploration of its anti-cancer potential. More details can be found in article 10.1002/cmdc.202500084 by Evamarie Hey-Hawkins and co-workers. Art by Christoph Selg.

查看原文本刊更多论文

封面专题：双氯芬酸衍生物的进展：探索碳硼烷取代的n -甲基和腈类似物用于抗癌治疗（ChemMedChem 11/2025）

就像尖刺有助于阻止鸟类降落在建筑立面上一样，碳硼烷取代的双氯芬酸中的战略性n-甲基化可以防止羧酸形成不必要的内酰胺，从而保持开链结构，以探索其抗癌潜力。更多细节可以在10.1002/cmdc中找到。202500084作者：Evamarie Hey-Hawkins及其同事。艺术由Christoph Selg。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ChemMedChem 医学-药学

CiteScore

6.70

自引率

2.90%

发文量

280

审稿时长

1 months

期刊介绍： Quality research. Outstanding publications. With an impact factor of 3.124 (2019), ChemMedChem is a top journal for research at the interface of chemistry, biology and medicine. It is published on behalf of Chemistry Europe, an association of 16 European chemical societies. ChemMedChem publishes primary as well as critical secondary and tertiary information from authors across and for the world. Its mission is to integrate the wide and flourishing field of medicinal and pharmaceutical sciences, ranging from drug design and discovery to drug development and delivery, from molecular modeling to combinatorial chemistry, from target validation to lead generation and ADMET studies. ChemMedChem typically covers topics on small molecules, therapeutic macromolecules, peptides, peptidomimetics, and aptamers, protein-drug conjugates, nucleic acid therapies, and beginning 2017, nanomedicine, particularly 1) targeted nanodelivery, 2) theranostic nanoparticles, and 3) nanodrugs. Contents ChemMedChem publishes an attractive mixture of: Full Papers and Communications Reviews and Minireviews Patent Reviews Highlights and Concepts Book and Multimedia Reviews.